A Polymarket prediction contract currently assigns a 92% probability that Ether (ETH) will reach $2,600 before the end of September. This follows a 7% price increase over the past 24 hours. The contract settles based on the highest one-minute candle price of ETH/USDT on Binance, with a "Yes" outcome if $2,600 is hit and "No" if not. This prediction market reflects trader sentiment but does not guarantee the price will reach that level.
Ether's chance of reaching $2,600 is currently predicted at 92% by Polymarket, providing a backdrop for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Sep 23, 2026 18:51 WIB: out of 50 major cryptocurrencies, 34 rose and 15 fell today. Notable movers include UNI at Rp173.419 with an 11.74% increase and a typical hold time of 65 days, COTI at Rp298 up 11.38% with a 120-day hold time, and XNO at Rp6.687 down 11.28% with an 86-day hold time.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Johnson & Johnson announced promising Phase 1 results for a novel immunotherapy combining pasritamig and JNJ-9401, targeting two prostate cancer proteins to activate T cells. In the trial, 73% of patients saw PSA levels drop by at least 50%, with nea...
